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Objective. The aim of this study was to investigate the expression of p63 protein in mucoepidermoid carcinoma and papillary
cystadenoma of the salivary glands, and to evaluate the usefulness of this protein in distinguishing these tumors.
Study Design. Immunoexpression of p63 protein was studied and quantified in 9 formalin-fixed paraffin-embedded mucous
retention cysts, 4 papillary cystadenomas, and 19 low-grade and 9 high-grade mucoepidermoid carcinomas.
Results. All cases were positive for p63 immunoexpression; however, it was observed that p63 labeling in mucous retention
cysts and papillary cystadenomas was limited to the basal layers of the cystic spaces, whereas in low-grade mucoepidermoid
carcinomas, positive nuclear staining was also found diffusely in the suprabasal layers. Mucoepidermoid carcinoma presented
increased immunoexpression of p63 compared with the other groups.
Conclusions. P63 immunohistochemical expression pattern can be helpful in distinguishing low-grade mucoepidermoid
carcinoma from papillary cystadenoma of the salivary glands. (Oral Surg Oral Med Oral Pathol Oral Radiol 2013;115:79-86)Mucoepidermoid carcinoma (MEC) is the most com-
mon malignant salivary gland tumor. In major salivary
glands it usually presents as a single painless mass,
whereas in minor glands it typically involves the palate,
presenting as a bluish swelling. Histologically, MEC is
characterized by neoplastic cells organized in solid and
cystic growth patterns, and is classified into low-, in-
termediate-, and high-grade types.1-4
Papillary cystadenoma of the salivary glands is a rare
benign epithelial tumor characterized by multicystic
growth, with focal intraluminal papillary proliferations
of the epithelial lining.5 Most cases occur in major
salivary glands, particularly the parotid gland, but these
can also be found in minor glands, being seen in the lip,
buccal mucosa and palate.6-8 Cystadenomas of the ma-
jor glands present as asymptomatic masses, but in the
oral cavity they may resemble mucoceles.7 Histologi-
cally, cystadenomas show a close resemblance to low-
grade MEC, particularly when the latter shows a pre-
dominantly cystic papillary growth pattern.
p63 protein is constitutively expressed in cell nuclei
of many normal stratified epithelial tissues, including
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In addition, p63 is strongly expressed in myoepithelial
cells of the breast and salivary glands.9-11 In neoplastic
tissues, p63 immunoreactivity has been demonstrated
in transitional and squamous cell carcinomas and in
several salivary gland tumors, including adenoid cystic
carcinoma, polymorphous low-grade adenocarcinoma,
and myoepithelial carcinoma.12
Different myoepithelial markers have been investi-
gated in MEC, with divergent and inconclusive results.
The expression of p63 has been the subject of very few
studies in this context.9,13,14 Moreover, the expression
of p63 in papillary cystadenoma has not been described
previously in the literature. Therefore, the aim of the
present study was to describe the immunoexpression of
p63 in MEC, papillary cystadenoma, and mucous re-
tention cysts, and evaluate if this marker could be
useful for the differentiating between MEC and papil-
lary cystadenoma.
MATERIALS AND METHODS
Nineteen low-grade MECs, 9 high-grade MECs, 4 pap-
illary cystadenomas, and 9 mucous retention cysts,
Statement of Clinical Relevance
The distinction between cystadenoma and low-
grade mucoepidermoid carcinoma is sometimes
challenging. The present study shows that p63 pro-
tein is expressed in both tumors, but with different
intensity and patterns, which may be useful in dis-
tinguishing the tumors.79
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were used to determine immunohistochemically the
expression of p63 protein. All samples were fixed in
10% formalin and embedded in paraffin. The original
diagnoses were reviewed by 2 independent oral pathol-
ogists, according to the World Health Organization
classification.2 For immunohistochemistry, 3-m sec-
tions were dewaxed with xylene and then hydrated in
an ethanol series. For antigen retrieval, slides were
immersed in 10 mmol/L monohydrated citrate buffer
(pH 6.0) and underwent 3 minutes of pressure cooking.
Endogenous peroxidase activity was blocked with the
use of 10% hydrogen peroxide in 5 baths, each for 5
minutes. After washing in phosphate-buffered saline
buffer (pH 7.4), slides were incubated overnight with
the primary antibody anti-p63 clone 4A4 (Dakocyto-
mation) diluted 1:300. All slides were subsequently
exposed to Advanced Kit (Dakocytomation) and di-
aminobenzidin tetrahydrochloride (DAB; Sigma) and
counterstained with Carazzi hematoxylin. Sections of
fibrous hyperplasia were used as positive control, and
the negative control was obtained by omitting the pri-
mary specific antibody. Results were considered to be
positive when cells showed strong brown nuclear stain-
ing.
Glass slides were subsequently scanned with the
Scanscope CS Slide Scanner (Aperio Technologies).
Digital images obtained were analyzed for p63 expres-
sion using the Imagescope software and its Nuclear
Staining V9 algorithm (Aperio Technologies), with the
purpose of quantifying the percentage of positive cells
in 5 hotspot areas in each case. The software recog-
nized positive expression as those with nuclear staining
that ranged from 80 to 230 pixels of intensity. Lower
values were considered to be nonspecific staining. For
statistical analysis, the software Graphpad Prism 5.0
was used and a P value of .05 was considered to be
statistically significant.
RESULTS
The clinical features are summarized in Table I. Mu-
cous retention cysts mainly involved the floor of the
mouth of female patients, with a mean age of 60.2 years
(range 24-72 years), and had presented as an asymp-
tomatic swelling of unknown duration. The 28 cases of
MEC corresponded to 17 women and 11 men, with a
mean age of 46.3 years (range 16-80 years). All papil-
lary cystadenomas occurred in women, with a mean age
of 60.5 years (range 50-71 years). Most cases of MEC
involved the palate, whereas 1 case of cystadenoma
involved the floor of the mouth, 2 the palate, and 1 the
buccal mucosa. The chief presenting complaint of MEC
and cystadenomas was of an asymptomatic swelling.Histologically, the majority of the mucous retentioncysts revealed a thin epithelial lining, usually composed
of only 1 or 2 cell layers, (Figure 1, A). In 2 cases a
prominent proliferation of the luminal cells was evi-
dent, with the presence of mucous cells in the epithelial
lining (Figure 1, B). An eosinophilic fluid in the lumen
of the cysts was invariably present. All 4 papillary
cystadenomas presented as variably sized well-circum-
scribed multicystic lesions with luminal papillary
growth but without an evident fibrous capsule (Figure
1, C). The epithelial lining of the cystic spaces was
mainly composed of 2 layers of cuboidal or columnar
cells that occasionally became thickened, forming
small sheets of a more solid growth. Scattered mucous
cells could be identified in all cases. In one case,
oncocytic cells predominated (Figure 1, D). Eosino-
philic amorphous fluid in the lumen of the cystic cav-
ities was frequently present. Cellular atypia and mitoses
were absent from all cases.
Low-grade MECs were mainly composed of variably
sized cystic spaces, showing papillary projections and
more solid areas (Figure 2, A). Depending on the area
evaluated, there was a predominance of mucous, inter-
mediate, or squamous cells (Figure 2, B). Clear cells
were present in several cases and predominated in 1
case (Figure 2, C). Mitoses and cellular atypia were rare
and foci of necrosis absent. High-grade MEC presented
as solid growths of intermediate and squamous cells,
with mucous cells present in variable amounts, partic-
ularly lining small cystic spaces and occasionally
among the squamous cells (Figure 2, D). Cytologic and
nuclear pleomorphism, as well as mitoses and an infil-
trative growth pattern into adjacent tissues were found
in all cases. Sclerotic areas were variable, with no
evident differences between MEC and papillary cysta-
denoma, except for 1 case of low-grade MEC that
showed intense sclerosis.
Normal minor salivary glands present in the sur-
gical specimens expressed nuclear positivity for p63
in the myoepithelial/basal cells of the ductal struc-
tures and at the periphery of the acinar cells. Simi-
larly, all mucous retention cysts and papillary cysta-
denomas revealed positive nuclear reactivity for p63,
almost exclusively in the basal cells of the cystic
structures. Occasionally, a few cells above the basal
layer were positive (Figure 3).
A variable staining pattern could be seen in all cases of
low- and high-grade MEC. Sheets of intermediate or
squamous cells were diffusely positive for p63, but in the
cystic spaces the expression of p63 was not restricted to
the basal cells and extended to the upper layers closer to
the lumen (Figure 4, A-C). It was also noted that in several
cystic spaces, the more basal cells did not show expression
of p63. Finally, p63 protein expression was negative in the
mucous and clear cells (Figure 4, D). With the use of
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Volume 115, Number 1 Fonseca et al. 81quantitative digital analysis, high-grade MEC cases re-
vealed the highest index of expression of p63 (56.7%),
followed by low-grade MEC (46.8%), mucous retention
cysts (23.1%), and papillary cystadenomas (22.0%). Anal-
ysis of variance showed a statistically significant differ-
ence among the 4 groups studied (P .0001). In addition,
with the use of Tukey post hoc test, a significant increase
in positive immunohistochemical staining for p63 protein
was observed in low- and high-grade MEC compared
with mucous retention cyst (both P  .0001) and cysta-
denoma (P  .001 and P  .0001, respectively). No
significant difference was observed between mucous re-
tention cyst and cystadenoma (P  .05) or between low-
Table I. Clinicopathologic features of mucous retent
(MECs)
Case Diagnosis Age
1 Retention cyst 63
2 Retention cyst 24
3 Retention cyst 71
4 Retention cyst 72
5 Retention cyst 65
6 Retention cyst 66
7 Retention cyst 60
8 Retention cyst NS





14 Low-grade MEC 63
15 Low-grade MEC 38
16 Low-grade MEC 75
17 Low-grade MEC 22
18 Low-grade MEC 44
19 Low-grade MEC 71
20 Low-grade MEC 41
21 Low-grade MEC 31
22 Low-grade MEC 38
23 Low-grade MEC 42
24 Low-grade MEC 62
25 Low-grade MEC 30
26 Low-grade MEC 49
27 Low-grade MEC 28
28 Low-grade MEC 64
29 Low-grade MEC NS
30 Low-grade MEC 35
31 Low-grade MEC NS
32 Low-grade MEC NS
33 High-grade MEC 67
34 High-grade MEC 16
35 High-grade MEC 80
36 High-grade MEC 28
37 High-grade MEC 45
38 High-grade MEC 17
39 High-grade MEC 42
40 High-grade MEC 52
41 High-grade MEC 78
NS, Not specified.and high-grade MEC (P  .05; Figure 5).DISCUSSION
The characteristic cystic growth pattern of low-grade
MEC, with varying degrees of intracystic projections,
can lead to a histologic similarity to papillary cystade-
noma. The distinction between both tumors is some-
times arbitrary, leading to wrong diagnosis and to in-
adequate surgical treatment. The present study showed
that p63 protein is expressed in both tumors, but with
different intensity and patterns, and therefore could be
useful in distinguishing between both tumor types.
The p63 gene, mapped to 3q27-29, is the third mem-
ber of the p53 family, whose transcription from 2
sts, cystadenomas, and mucoepidermoid carcinomas
Site Clinical presentation
Superior lip Asymptomatic nodule
Floor of mouth Asymptomatic nodule
Floor of mouth Asymptomatic nodule
Buccal mucosa Asymptomatic nodule
Superior lip Asymptomatic nodule
Buccal mucosa Asymptomatic nodule
Floor of mouth Asymptomatic nodule
Floor of mouth Asymptomatic nodule
Floor of mouth Asymptomatic nodule
Buccal mucosa Asymptomatic nodule
Palate Asymptomatic nodule
Palate Swelling
Floor of mouth Asymptomatic nodule
Maxilla, NOS NS
Buccal mucosa NS
Hard palate Asymptomatic nodule
Hard and soft palate Asymptomatic nodule
Mandible NS
Retromolar area Painful swelling
Palate Asymptomatic nodule
Hard palate Asymptomatic nodule
Hard palate NS
NS Painful swelling
Hard and soft palate NS
Soft palate Asymptomatic nodule
Hard palate Painful swelling
Soft palate Asymptomatic nodule
Hard and soft palate NS
Maxilla Asymptomatic swelling
Hard palate Painful swelling
Hard palate Swelling
Hard palate Swelling
Hard palate Asymptomatic nodule
Soft palate Asymptomatic nodule
Superior lip Painful swelling
Buccal mucosa Asymptomatic nodule
Retromolar área Asymptomatic nodule
Hard and soft palate Painful swelling
Hard palate NS
Buccal mucosa Asymptomatic nodule
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in at least 6 different isoforms.9,10 The TAp63 isoform
activates p53 target genes (p21waf1/cip1, mdm2, and
bax), blocks cell cycle progression, and promotes apo-
ptosis, whereas the Np63 isoform acts in a dominant
negative manner, inhibiting the transcriptional activa-
tion of the p53 gene.9,12-15 The only commercially
available antibody against p63 protein has shown to be
limited in the ability to discriminate between TAp63
and Np63, because it recognizes both isoforms.
In humans, p63 is expressed in many normal epithe-
lial tissues and seems to be relevant for epithelial stem
cell survival and maturation. Furthermore, p63 is a
selective nuclear marker of normal myoepithelial cells
in the human breast and salivary glands.11,14-16
Although somatic mutation of the p63 gene is not a
classic oncogenic event in neoplasia the p63 protein is
overexpressed in various neoplasms, particularly squa-
mous carcinomas of the aerodigestive tract, lung, skin,
and uterine cervix, and benign and malignant myoepi-
theliomas.13,15,17,18 In contrast, Jo and Fletcher (2011)
reported that expression of p63 is practically absent in
Fig. 1. Histologic features of mucous retention cyst (MRC) an
epithelium composed of 2 cellular layers (HE, 200). B, In
of mucous cells (HE, 100). C, Papillary cystadenoma with c
(HE, 200). D, Papillary cystadenoma presenting predomina
became thickened, leading to a more solid growth pattern (Hnormal and malignant mesenchymal cells.19 Salivarygland tumors have also been studied for p63 expres-
sion, and neoplasias that show proliferation of myoep-
ithelial cells, such as pleomorphic adenoma, myoepi-
thelioma, basal cell adenoma, adenoid cystic
carcinoma, polymorphous low-grade adenocarcinoma,
epithelial-myoepithelial carcinoma, myoepithelial car-
cinoma, and basal cell adenocarcinoma widely express
p63 protein depending on their myoepithelial con-
tent.10,12,14,20,21
MEC has classically been considered to be a neo-
plasm devoid of myoepithelal cells; however, the par-
ticipation of these cells in the oncogenesis of MEC is
now a matter of controversy.22 According to Dardick et
al. (1996),23 MEC derives from both luminal and non-
luminal cells, with a growth pattern characterized by
the presence of luminal epithelial cells surrounded by
intermediate cells, which were considered to be modi-
fied myoepithelial cells. Other studies have investigated
the immunoexpression of myoepithelial markers in
MEC, especially those relating to smooth muscle anti-
gens such as -smooth muscle actin, caldesmon, and
calponin, but the results obtained have been variable
llary cystadenoma. A, Cystic space of MRC is lined by a thin
s of MRC, epithelial lining was prominent with the presence
paces lined by epithelium showing intracystic luminal growth







Volume 115, Number 1 Fonseca et al. 83There are few studies describing the expression of
p63 protein in MEC. García et al. (2011),27 Bilal et al.
(2003),9 Mitani et al. (2011),14 Weinreb et al. (2009),28
and Seethala et al. (2005)13 evaluated the immunoex-
pression of p63 in MEC, and all cases showed variable
proportions of cells with nuclear positivity for p63.
Similarly, Maruya et al. (2005) observed that 66.7% of
MECs in their study were positive for p63 protein.12
These results were explained by the presence of inter-
mediate and squamous cells, which would represent
modified myoepithelial cells, further supporting the ul-
trastructural results obtained previously that revealed
the presence of myofilaments in these cells, which
would have been responsible for -smooth muscle actin
positive reactions.26,29 Similarly to the the studies by
García et al.27 and by Weinreb et al.28 which evaluated
p63 immunoexpression in oncocytic MEC, in the pres-
ent study it was observed that cells positive for p63 in
MEC represented both intermediate and squamous cells
of the solid growth areas and of the lining cystic spaces,
where the immunoexpression was not limited to the
basal layer, highlighting the multilayered intermediate-/
squamous-type cells of these cystic spaces. In addition,
with the use of digital analysis it was observed that low-
Fig. 2. Histologic features of mucoepidermoid carcinoma (M
cystic spaces lined by mucous, intermediate, and squamous c
(HE, 200). D, High-grade MEC showing solid growths ofand high-grade MEC showed an increased expressionof p63 compared with mucous retention cysts and pap-
illary cystadenomas, which may be related to the pre-
dominance of intermediate and squamous cells in these
tumors, as has also been reported by Maruya et al.12
and Seethala et al.13 It is notable that mucous cells and
clear cells, which can predominate in some cases of
MEC, were negative for p63.
Papillary cystadenoma of the salivary gland is a
well circumscribed multicystic benign epithelial neo-
plasm showing intracystic papillary projections of its
epithelial lining.6,8 Most cases are lined by columnar
or cuboidal cells, but a predominance of oncocytic
cells, resembling Warthin tumor, is not uncommon,
as was the case in 1 of our 4 samples.5 Cystadenomas
of the salivary gland are rare, with few cases re-
ported, and usually not included in large series or
reviews of salivary gland tumors, being occasionally
misdiagnosed as either low-grade MEC or mucous
retention cysts showing multiple cavities.8,30
There are no studies considering the immunoex-
pression of p63 in mucous retention cysts and in
cystadenomas of salivary glands. In the present
study, it was observed that cells expressing p63 were
mainly located in the basal layer of the epithelial
A, B, Low-grade MEC mainly composed of variably sized
E, 100). C, Predominance of clear cells in a case of MEC
stic cells with scarce cystic spaces (HE, 100).EC).
ells (Hlining of the cystic spaces of the mucous retention
especti
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cells. However, in several cases positive nuclear
staining was very difficult to identify, and in some
areas this positivity could not be observed, which
may have been due to the extremely thin epithelial
lining present in these cases which prevented proper
detection of positive nuclei. More interestingly, the
labeling pattern observed in all cases of papillary
cystadenomas was also restricted to the basal layers,
suggesting that the cystic spaces present in these
tumors keep a similarity to normal ducts, as de-
scribed in our cases of mucous retention cysts and
Fig. 3. P63 protein immunoexpression in mucous retention c
staining in basal cells of the cystic epithelium of MRC (200
of papillary cystadenoma (100, 200, 400, and 400, rpreviously reported for necrotizing sialometapla-sia.31 This labeling pattern also indicates that the
proliferative cells in cystadenomas are the luminal
ones, as proposed by Dardick et al. (1996).23 In
low-grade MEC, p63 showed a distinct expression
pattern, staining cells in all layers of the epithelial
lining of the cystic spaces, although not uniformly in
all cases. In fact, the loss of distinct and normal
basal/myoepithelial cells found in some cystic spaces
in MEC is a strong indication of malignancy, as
characteristically occurs in breast and prostate can-
cer.11,16
In conclusion, the staining pattern of p63 protein in
C) and papillary cystadenoma. A, B, MRC showing nuclear
100, respectively). C, D, E, F, Positive staining in basal cells
vely).yst (MR
and papillary cystadenoma and low-grade MEC could be
OOOO ORIGINAL ARTICLE
Volume 115, Number 1 Fonseca et al. 85helpful in the diagnosis in cases posing histologic dif-
ficulties. Moreover, a higher percentage of cells were
Fig. 4. P63 immunoexpression in mucoepidermoid carcinom
intermediate and squamous cells, not only in the basal cells
projections (100). C, P63 immunoexpression was absent in
reactivity in intermediate and squamous cells (200).
Fig. 5. Percentage of stained cells for p63 protein in mucous
retention cyst (MRC), papillary cystadenoma, low-grade mu-
coepidermoid carcinoma (MEC), and high-grade MEC. Anal-
ysis of variance: P  .0001. aSignificant difference between
MRC and low- and high-grade MEC (P  .0001). bSignifi-
cant difference between papillary cystadenoma and low-grade
MEC (P  .001). cSignificant difference between papillary
cystadenoma and high-grade MEC (P  .0001).positive for p63 in high-grade MEC compared withlow-grade tumors, and much lower indexes were found
in mucous retention cysts and papillary cystadenomas.
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